Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
NCT01556490
Interventional
Not Applicable
Completed
STOP-HCC
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
Mar 31,2012
All
18 Years
N/A
18 Years
N/A
526